Pfizer (PFE) Q2 FY26 earnings call

Pfizer delivered a strong Q2 FY26, driven by robust performance in its non-COVID portfolio and acquired assets, leading to a raise in full-year revenue guidance despite lower COVID-19 product sales. The company continues to advance a deep R&D pipeline, particularly in oncology and obesity, while expanding cost-saving initiatives and reaffirming its commitment to dividend growth post-LOE period. Strategic investments in AI are also accelerating productivity across the business.